Inhaled therapy for the management of perioperative pulmonary hypertension.
Loading...
Date
2015-07
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Patients with pulmonary hypertension (PH) are at high risk for complications in the perioperative setting
and often receive vasodilators to control elevated pulmonary artery pressure (PAP). Administration of
vasodilators via inhalation is an effective strategy for reducing PAP while avoiding systemic side effects,
chiefly hypotension. The prototypical inhaled pulmonary‑specific vasodilator, nitric oxide (NO), has a proven
track record but is expensive and cumbersome to implement. Alternatives to NO, including prostanoids (such
as epoprostenol, iloprost, and treprostinil), NO‑donating drugs (sodium nitroprusside, nitroglycerin, and
nitrite), and phosphodiesterase inhibitors (milrinone, sildenafil) may be given via inhalation for the purpose
of treating elevated PAP. This review will focus on the perioperative therapy of PH using inhaled vasodilators.
Description
Keywords
Nitric oxide‑donating drugs, Phosphodiesterase inhibitors, Prostanoids, Prototypical inhaled, pulmonary‑specific vasodilator
Citation
Thunberg C A, Morozowich S T, Ramakrishna Harish. Inhaled therapy for the management of perioperative pulmonary hypertension. Annals of Cardiac Anaesthesia. 2015 Jul; 18(3): 394-402.